19 April 2022 in Cell Reports
MFMaría Fernández-Casañas
+1
Mitotic DNA synthesis (MiDAS) has been proposed to restart DNA synthesis during mitosis because of replication fork stalling in late interphase caused by mild replication stress (RS). Contrary to this proposal, we find that cells exposed to mild RS in fact maintain continued DNA replication throughout G2 and during G2-M transition in RAD51- and RAD52-dependent manners. Persistent DNA synthesis is necessary to resolve replication intermediates accumulated in G2 and disengage an ATR-imposed block to mitotic entry. Because of its continual nature, DNA synthesis at very late replication sites can overlap with chromosome condensation, generating the phenomenon of mitotic DNA synthesis. Unexpectedly, we find that the commonly used CDK1 inhibitor RO3306 interferes with replication to preclude detection of G2 DNA synthesis, leading to the impression of a mitosis-driven response. Our study reveals the importance of persistent DNA replication and checkpoint control to lessen the risk for severe genome under-replication under mild RS.
23 May 2024 in JCI Insight
The nonphysiological nutrient levels found in traditional culture media have been shown to affect numerous aspects of cancer cell physiology, including how cells respond to certain therapeutic agents. Here, we comprehensively evaluated how physiological nutrient levels affect therapeutic response by performing drug screening in human plasma-like medium. We observed dramatic nutrient-dependent changes in sensitivity to a variety of FDA-approved and clinically trialed compounds, including rigosertib, an experimental cancer therapeutic that recently failed in phase III clinical trials. Mechanistically, we found that the ability of rigosertib to destabilize microtubules is strongly inhibited by the purine metabolism end product uric acid, which is uniquely abundant in humans relative to traditional in vitro and in vivo cancer models. These results demonstrate the broad and dramatic effects nutrient levels can have on drug response and how incorporation of human-specific physiological nutrient medium might help identify compounds whose efficacy could be influenced in humans.
1 January 2021 in SSRN Electronic Journal
MFMaría Fernández-Casañas
+1
Incomplete DNA replication caused by replication stress (RS) has been implicated in chromosome fragility, chromosome mis-segregation and genome instability. To counteract this, an unscheduled DNA synthesis pathway, MiDAS, has been proposed to rescue replication stalling after mitotic entry. It remains unclear why stressed replication forks fail to proceed during late interphase. Here we find that, contrary to the MiDAS model, human cells in fact actively maintain DNA synthesis throughout the entirety of G2 phase in face of mild RS. Besides, the persistent DNA replication activity in G2 is necessary for cells to proceed to mitosis. This is because the passage of unresolved replication structures, either in a retarded or stalled state, from S to G2 activates an ATR-dependent replication-stress checkpoint, blocking mitotic entry. Crucially, G2 DNA synthesis alongside associated G2/M delay creates a feedback mechanism to minimise genome under-replication. Acute inactivation of the RS checkpoint in G2 phase causes severe mitotic chromosome malformation; whereas prolonging G2 DNA synthesis effectively suppresses RS-induced DNA damage in offspring cells. Therefore, our study reveals another important role of G2 phase as an “emergency replication window” and, most importantly, demonstrates the biological necessity of DNA replication outside of S phase. This also offer an explanation for why ATR becomes so vital in G2 uniquely in cells experiencing RS. Understanding the plasticity of the replication programme may provide new insights into how (pre)cancerous cells withstand high intrinsic RS.